French bill tightens up on safety and conflicts of interest, but not drug approval criteria
This article was originally published in SRA
Longer waits before starting promotional campaigns, higher costs associated with new product approvals, and a sharp fall in sales rep employment levels: All are in prospect for the pharmaceutical industry if the new French bill on regulatory reform is passed in its present form1.
You may also be interested in...
Efforts are under way in the UK on many fronts to develop new treatments and vaccines for coronavirus infection, including researching new uses of existing products and clinical trials of new vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
AMD patients in the UK can legitimately be given compounded bevacizumab (Roche’s Avastin) after the appeals court said NHS trusts could offer a drug off-label for economic reasons where there were no safety or efficacy concerns.